SCHEMBL18521008

SCHEMBL18521008

COP(=O)(O)O[C@H]1C[C@@H](CO)O[C@H]1n1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FUT5 Q11128 1/20 0.55
▸ NT5E P21589 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HPRT1 P00492 3/20 0.49
▸ TGM2 P21980 1/20 0.49
▸ POLB P06746 1/20 0.47
▸ HINT1 P49773 1/20 0.46
▸ F2 P00734 1/20 0.45
▸ KRAS P01116 2/20 0.45
▸ PNP P00491 2/20 0.44
▸ TLR7 Q9NYK1 1/20 0.44
▸ P2RY2 P41231 1/20 0.44
▸ P2RY4 P51582 1/20 0.44
▸ P2RY6 Q15077 1/20 0.44
▸ GSK3A P49840 1/20 0.44
▸ RPS6KA3 P51812 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31583575 0.92 FUT5 (0.53) FUT5NT5EHPGDHPRT1TGM2
SCHEMBL30612754 0.89 HPGD (0.54) FUT5NT5EHPGDHPRT1HINT1
SCHEMBL20833471 0.87 HPGD (0.51) FUT5NT5EHPGDHPRT1TGM2
SCHEMBL21539237 0.86 FUT5 (0.48) FUT5NT5EHPGDHPRT1TGM2
SCHEMBL21539254 0.86 FUT5 (0.50) FUT5NT5EHPGDHPRT1TGM2
SCHEMBL25711923 0.84 HINT1 (0.50) FUT5NT5EHPGDHPRT1HINT1
SCHEMBL12714596 0.84 FUT5 (0.66) FUT5NT5EHPRT1TGM2POLB
Phosphoric Acid SCHEMBL16213328 0.83 NT5E (0.54) FUT5NT5EHPGDHPRT1TGM2
SCHEMBL22326749 0.83 FUT5 (0.53) FUT5NT5ETGM2
SCHEMBL12714572 0.82 FUT5 (0.61) FUT5NT5EHPRT1TGM2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044206-A1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS STING1, CGAS, IFNAR1 FUT5 4404/4885NT5E 1372/4885HPGD 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback